Metformin and the sulfonylureas are the most heavily prescribed drugs in T2D and dominate the early lines of therapy prior to disease progression, which requires insulin replacement. The emergence of more-effective, safer, and/or better-tolerated therapies, such as the DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists, have provided physicians with a broad array of therapeutic options. Moreover, with a better understanding of type 2 diabetes and its complications, individualized treatment for patients is becoming more commonplace. Numerous branded agents from both established and recently emergent classes are now jostling for position in the treatment paradigm.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
KEY DRUGS COVERED
Afrezza, Apidra, Basaglar, Bydureon, Byetta, Farxiga, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, Metformin, Nesina, Novolog, Onglyza, Ozempic, Toujeo, Tradjenta, Tresiba, Trulicity, Victoza
KEY ANALYSIS PROVIDED